Literature DB >> 11790852

Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.

Nancy M King1, Laurence Melnick, Moses Prabu-Jeyabalan, Ellen A Nalivaika, Shiow-Shong Yang, Yun Gao, Xiaoyi Nie, Charles Zepp, Donald L Heefner, Celia A Schiffer.   

Abstract

The three-dimensional structures of indinavir and three newly synthesized indinavir analogs in complex with a multi-drug-resistant variant (L63P, V82T, I84V) of HIV-1 protease were determined to approximately 2.2 A resolution. Two of the three analogs have only a single modification of indinavir, and their binding affinities to the variant HIV-1 protease are enhanced over that of indinavir. However, when both modifications were combined into a single compound, the binding affinity to the protease variant was reduced. On close examination, the structural rearrangements in the protease that occur in the tightest binding inhibitor complex are mutually exclusive with the structural rearrangements seen in the second tightest inhibitor complex. This occurs as adaptations in the S1 pocket of one monomer propagate through the dimer and affect the conformation of the S1 loop near P81 of the other monomer. Therefore, structural rearrangements that occur within the protease when it binds to an inhibitor with a single modification must be accounted for in the design of inhibitors with multiple modifications. This consideration is necessary to develop inhibitors that bind sufficiently tightly to drug-resistant variants of HIV-1 protease to potentially become the next generation of therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11790852      PMCID: PMC2373441          DOI: 10.1110/ps.25502

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  36 in total

1.  WHAT IF: a molecular modeling and drug design program.

Authors:  G Vriend
Journal:  J Mol Graph       Date:  1990-03

2.  Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo.

Authors:  J Ermolieff; X Lin; J Tang
Journal:  Biochemistry       Date:  1997-10-07       Impact factor: 3.162

3.  Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.

Authors:  P J Ala; E E Huston; R M Klabe; D D McCabe; J L Duke; C J Rizzo; B D Korant; R J DeLoskey; P Y Lam; C N Hodge; C H Chang
Journal:  Biochemistry       Date:  1997-02-18       Impact factor: 3.162

Review 4.  Recent developments in HIV protease inhibitor therapy.

Authors:  A Molla; G R Granneman; E Sun; D J Kempf
Journal:  Antiviral Res       Date:  1998-07       Impact factor: 5.970

5.  Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition.

Authors:  S I Wilson; L H Phylip; J S Mills; S V Gulnik; J W Erickson; B M Dunn; J Kay
Journal:  Biochim Biophys Acta       Date:  1997-04-25

6.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.

Authors:  S V Gulnik; L I Suvorov; B Liu; B Yu; B Anderson; H Mitsuya; J W Erickson
Journal:  Biochemistry       Date:  1995-07-25       Impact factor: 3.162

7.  Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials.

Authors:  Z Chen; Y Li; H B Schock; D Hall; E Chen; L C Kuo
Journal:  J Biol Chem       Date:  1995-09-15       Impact factor: 5.157

8.  Structure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugs.

Authors:  L Hong; X J Zhang; S Foundling; J A Hartsuck; J Tang
Journal:  FEBS Lett       Date:  1997-12-22       Impact factor: 4.124

9.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

10.  Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases.

Authors:  Z Chen; Y Li; E Chen; D L Hall; P L Darke; C Culberson; J A Shafer; L C Kuo
Journal:  J Biol Chem       Date:  1994-10-21       Impact factor: 5.157

View more
  44 in total

1.  Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.

Authors:  Mark D Shenderovich; Ron M Kagan; Peter N R Heseltine; Kal Ramnarayan
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

2.  The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.

Authors:  Rajintha M Bandaranayake; Madhavi Kolli; Nancy M King; Ellen A Nalivaika; Annie Heroux; Junko Kakizawa; Wataru Sugiura; Celia A Schiffer
Journal:  J Virol       Date:  2010-07-21       Impact factor: 5.103

3.  Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir.

Authors:  Xianfeng Chen; Irene T Weber; Robert W Harrison
Journal:  J Mol Model       Date:  2004-09-28       Impact factor: 1.810

4.  Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.

Authors:  José C Clemente; Roxana M Coman; Michele M Thiaville; Linda K Janka; Jennifer A Jeung; Sarawut Nukoolkarn; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Robert McKenna; Wichet Leelamanit; Maureen M Goodenow; Ben M Dunn
Journal:  Biochemistry       Date:  2006-05-02       Impact factor: 3.162

5.  Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance.

Authors:  Mina Henes; Gordon J Lockbaum; Klajdi Kosovrasti; Florian Leidner; Gily S Nachum; Ellen A Nalivaika; Sook-Kyung Lee; Ean Spielvogel; Shuntai Zhou; Ronald Swanstrom; Daniel N A Bolon; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  ACS Chem Biol       Date:  2019-08-13       Impact factor: 5.100

6.  HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.

Authors:  Michael D Altman; Akbar Ali; G S Kiran Kumar Reddy; Madhavi N L Nalam; Saima Ghafoor Anjum; Hong Cao; Sripriya Chellappan; Visvaldas Kairys; Miguel X Fernandes; Michael K Gilson; Celia A Schiffer; Tariq M Rana; Bruce Tidor
Journal:  J Am Chem Soc       Date:  2008-04-16       Impact factor: 15.419

7.  Novel method for probing the specificity binding profile of ligands: applications to HIV protease.

Authors:  Woody Sherman; Bruce Tidor
Journal:  Chem Biol Drug Des       Date:  2008-03-31       Impact factor: 2.817

8.  Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease.

Authors:  Ayşegül Özen; Kuan-Hung Lin; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-29       Impact factor: 11.205

9.  Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease.

Authors:  Jennifer E Foulkes-Murzycki; Christina Rosi; Nese Kurt Yilmaz; Robert W Shafer; Celia A Schiffer
Journal:  ACS Chem Biol       Date:  2012-12-27       Impact factor: 5.100

Review 10.  Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

Authors:  Eric Lefebvre; Celia A Schiffer
Journal:  AIDS Rev       Date:  2008 Jul-Sep       Impact factor: 2.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.